CIBC Upgrades Progenics Pharmaceuticals

Analyst Matt Geller says he expects positive results for the pharmaceutical company's trials for methylnaltrexone

CIBC World upgrades Progenics Pharmaceuticals (PGNX ) to sector outperform from sector perform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.